Exelixis
EXEL
#1694
Rank
C$13.82 B
Marketcap
$48.40
Share price
0.70%
Change (1 day)
68.49%
Change (1 year)
Exelixis, Inc. is an American genomics-based drug discovery company and the producer of Cometriq, a treatment for medullary thyroid cancer.

Earnings for Exelixis (EXEL)

Earnings in 2024 (TTM): C$0.81 Billion

According to Exelixis's latest financial reports the company's current earnings are C$2.08 Billion. In 2023 the company made an earning of C$0.35 Billion, an increase over its 2022 earnings that were of C$0.32 Billion. The earnings displayed on this page is the company's Pretax Income.

Earnings history for Exelixis from 2000 to 2024

Annual earnings

Year Earnings Change
2024 (TTM) C$0.81 B126.14%
2023 C$0.35 B9.89%
2022 C$0.32 B-20.33%
2021 C$0.41 B124.82%
2020 C$0.18 B-67.14%
2019 C$0.55 B-11.94%
2018 C$0.63 B185.09%
2017 C$0.22 B-325.82%
2016 -C$98.09 Million-58.12%
2015 -C$0.24 Billion-37.61%
2014 -C$0.38 Billion9.75%
2013 -C$0.35 Billion65.96%
2012 -C$0.21 Billion-291.63%
2011 C$0.10 B-195.59%
2010 -C$0.12 Billion-42.17%
2009 -C$0.2 Billion-18.98%
2008 -C$0.25 Billion-6.99%
2007 -C$0.26 Billion46.3%
2006 -C$0.18 Billion33.25%
2005 -C$0.14 Billion-30.92%
2004 -C$0.2 Billion44.29%
2003 -C$0.14 Billion12.86%
2002 -C$0.12 Billion22.79%
2001 -C$95.88 Million60.14%
2000 -C$59.87 Million

Earnings for similar companies or competitors

Company Earnings Earnings differencediff. Country
C$5.82 B 595.25%๐Ÿ‡ฌ๐Ÿ‡ง UK
C$10.34 B 1,134.83%๐Ÿ‡ซ๐Ÿ‡ท France
C$23.03 B 2,648.76%๐Ÿ‡บ๐Ÿ‡ธ USA
-C$9.61 Billion-1,246.85%๐Ÿ‡บ๐Ÿ‡ธ USA
C$6.53 B 679.96%๐Ÿ‡บ๐Ÿ‡ธ USA
C$25.69 B 2,966.31%๐Ÿ‡บ๐Ÿ‡ธ USA
-C$1.7 Billion-302.03%๐Ÿ‡บ๐Ÿ‡ธ USA
-C$65.11 Million-107.77%๐Ÿ‡บ๐Ÿ‡ธ USA
-C$40.57 Million-104.84%๐Ÿ‡บ๐Ÿ‡ธ USA